Late last Friday, the FDA authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include children 5 through 11 years of age.
The authorization was based on the FDA’s evaluation of data that included input from independent advisory committee experts who overwhelmingly voted in favor of making the vaccine available to children in this age group.
The FDA emphasized key points on effectiveness and safety. On effectiveness, the FDA stated that immune responses of children 5 through 11 years of age were comparable to those of individuals 16 through 25 years of age.
